Pegsunercept
From Infogalactic: the planetary knowledge core
| Clinical data | |
|---|---|
| Legal status |
|
| Routes of administration |
subcutaneous injection |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Identifiers | |
| CAS Number | 330988-75-5  |
| ATC code | none |
| UNII | Q5I7SFZ853  |
| KEGG | D05393 |
| Chemical data | |
| Formula | C502H758N154O165S16 |
| Molecular mass | 12,103 g/mol (protein part) |
| (what is this?) (verify) |
|
Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010[update], Phase II clinical trials have been completed.[1][2][3] It is being developed by Amgen.
Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.[3]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." /><templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- ↑ Clinical trial number NCT00037700 for "Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis" at ClinicalTrials.gov
- ↑ Clinical trial number NCT00111423 for "Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)" at ClinicalTrials.gov
- ↑ 3.0 3.1 Lua error in package.lua at line 80: module 'strict' not found.
Categories:
- Pages with reference errors
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs not assigned an ATC code
- TNF inhibitors
- Immunosuppressants
- Antineoplastic and immunomodulating drug stubs
